Increased Plasma Kynurenic Acid Levels are Associated with Impaired Attention/Vigilance and Social Cognition in Patients with Schizophrenia
Authors Huang X, Ding W, Wu F, Zhou S, Deng S, Ning Y
Received 23 November 2019
Accepted for publication 13 January 2020
Published 23 January 2020 Volume 2020:16 Pages 263—271
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Jun Chen
Xingbing Huang, 1, 2,* Wenhua Ding, 2,* Fengchun Wu, 2 Sumiao Zhou, 2 Shuhua Deng, 2 Yuping Ning 1– 3
1First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; 2The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, Guangdong, People’s Republic of China; 3Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yuping Ning
36 Mingxin Road, Liwan District, Guangzhou, People’s Republic of China
Tel +86 20 8189 1425
Fax +86 20 8189 1391
Objective: Preclinical studies have reported that abnormal kynurenic acid (KYNA) may play a role in cognitive deficits. Schizophrenia (SCZ) is characterized by a wide range of cognitive deficits that may evolve from abnormal KYNA. This study aimed to explore the relationship between KYNA and cognitive impairment in SCZ, which has not yet been reported.
Methods: We recruited 30 SCZ patients and 34 healthy controls, measured clinical symptoms by using the Positive and Negative Syndrome Scale and performed cognitive tests using the MATRICS Consensus Cognitive Battery (MCCB). Plasma levels of tryptophan, kynurenine, and KYNA were determined by high-performance liquid chromatography–tandem mass spectrometry.
Results: We found that plasma KYNA levels were significantly higher in patients than in healthy controls (p=0.009). The cognitive performance of patients in the total MCCB scores and the scores of all subscales were significantly lower than those in healthy controls (all P < 0.01). Correlation analysis showed that KYNA levels were negatively correlated with attention/vigilance (r=– 0.457, p=0.019) and social cognition (r=– 0.481, p=0.013) only in SCZ patients.
Conclusion: Our results indicate that elevated plasma KYNA levels may serve as a biomarker of cognitive impairment in SCZ patients.
Keywords: schizophrenia, kynurenic acid, cognitive impairment, symptom
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]